Scinai Immunotherapeutics Ltd.
NASDAQ: SCNI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Amir Reichman
- Employees
- 31
- Headquarters
- Jerusalem, Israel
- IPO year
- 2015
- Market cap
- $358.0K
- Website
- https://www.scinai.com
Loading SCNI…
Loading profile data…Frequently asked questions about SCNI
What does Scinai Immunotherapeutics Ltd. (SCNI) do?
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licens...
Where does SCNI trade?
Scinai Immunotherapeutics Ltd. (SCNI) trades on the NASDAQ Capital Market.
What sector is SCNI in?
Scinai Immunotherapeutics Ltd. (SCNI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Scinai Immunotherapeutics Ltd.?
Amir Reichman is the chief executive officer of Scinai Immunotherapeutics Ltd. (SCNI).
Where is Scinai Immunotherapeutics Ltd. headquartered?
Scinai Immunotherapeutics Ltd. is headquartered in Israel.
Does SCNI pay a dividend?
Scinai Immunotherapeutics Ltd. (SCNI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SCNI go public?
Scinai Immunotherapeutics Ltd. (SCNI) completed its initial public offering in 2015.
Is SCNI an ADR?
Yes — SCNI is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Scinai Immunotherapeutics Ltd. reporting and dividends follow the underlying issuer.